Abstract
Vx-001, an HLA-A*0201 restricted telomerase (TERT)-specific anti-tumor vaccine, is composed of the 9-mer cryptic TERT572 peptide and its optimized variant TERT572Y. We have previously shown that Vx-001 is non-toxic, highly immunogenic and in vaccinated NSCLC patients early specific immune response is associated with prolonged survival. The aim of the present study was to investigate the specific T-cell immune response against Vx-001. Fifty-five patients with chemo-resistant advanced solid tumors were vaccinated with TERT572Y (2 subcutaneous injections) followed by TERT572 peptide (4 subcutaneous injections) every 3 weeks. Specific immune response was evaluated by IFN-γ and perforin ELISpot and intracellular cytokine staining assays. TERT-reactive T cells were detected in 27 (51%) out of 53 evaluable patients after the 2nd vaccination and in 22 (69%) out of 32 evaluable patients after the completion of 6 vaccinations. Immune responses developed irrespective of the stage of disease and disease status before vaccination. Patients with disease progression at study entry who developed a post-vaccination-induced immunological response had a significant overall survival benefit compared to the post-vaccination non-responders. The Vx-001 vaccine is a promising candidate for cancer immunotherapy since it can induce a TERT-specific T-cell immune response that is associated with prolonged survival.
Similar content being viewed by others
References
Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U (2003) Natural T cell immunity against cancer. Clin Cancer Res 9:4296–4303
Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90:1–50
van der Bruggen P, Zhang Y, Chaux P et al (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188:51–64
Blasco MA (2005) Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 6:611–622
Kim NW, Piatyszek MA, Prowse KR et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011–2015
Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA (1999) Creation of human tumour cells with defined genetic elements. Nature 400:464–468
Hahn WC, Stewart SA, Brooks MW et al (1999) Inhibition of telomerase limits the growth of human cancer cells. Nat Med 5:1164–1170
Robbins PF, Kawakami Y (1996) Human tumor antigens recognized by T cells. Curr Opin Immunol 8:628–636
Van PA, van der BP, Coulie PG et al (1995) Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145:229–250
Tourdot S, Scardino A, Saloustrou E et al (2000) A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 30:3411–3421
Gross DA, Graff-Dubois S, Opolon P et al (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113:425–433
Scardino A, Gross DA, Alves P et al (2002) HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168:5900–5906
Hernandez J, Garcia-Pons F, Lone YC et al (2002) Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci USA 99:12275–12280
Mavroudis D, Bolonakis I, Cornet S et al (2006) A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. Oncology 70:306–314
Bolonaki I, Kotsakis A, Papadimitraki E et al (2007) Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 25:2727–2734
Meijer SL, Dols A, Jensen SM et al (2007) Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209–2 M peptide. J Immunother 30:533–543
Rosenberg SA, Yang JC, Schwartzentruber DJ et al (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321–327
Parkhurst MR, Salgaller ML, Southwood S et al (1996) Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157:2539–2548
Valmori D, Fonteneau JF, Lizana CM et al (1998) Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160:1750–1758
Bercovici N, Haicheur N, Massicard S et al (2008) Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 31:101–112
Zuber B, Levitsky V, Jonsson G et al (2005) Detection of human perforin by ELISpot and ELISA: ex vivo identification of virus-specific cells. J Immunol Methods 302:13–25
De Vries IJM, Lesterhuis WJ, Barentsz JO et al (2005) Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 23:1407–1413
Slingluff CL Jr, Petroni GR, Yamshchikov GV et al (2004) Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 22:4474–4485
Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP (1999) Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol 162:3273–3279
Aruga A, Aruga E, Tanigawa K, Bishop DK, Sondak VK, Chang AE (1997) Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol 159:664–673
Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D (1995) Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother 41:151–156
Yang AS, Lattime EC (2003) Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 63:2150–2157
Gabriel EM, Lattime EC (2007) Anti-CTL-associated antigen 4: are regulatory T cells a target? Clin Cancer Res 13:785–788
Hodi FS, Mihm MC, Soiffer RJ et al (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712–4717
Korman A, Yellin M, Keler T (2005) Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs 6:582–591
Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459–465
Phan GQ, Yang JC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372–8377
Sun J, Schiffman J, Raghunath A, Ng TD, Chen H, Sharma P (2008) Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 8:9
Ling KL, Pratap SE, Bates GJ et al (2007) Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 7:7
O’Mahony D, Morris JC, Quinn C et al (2007) A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 13:958–964
Sakaguchi S (2000) Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101:455–458
Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6:345–352
Yamaguchi T, Sakaguchi S (2006) Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 16:115–123
Acknowledgments
Supported by the Cretan Association for Biomedical Research.
Conflict of interest
K. Kosmatopoulos and J. Menez-Jamet are employees and shareholders of Vaxon Biotech. All the other authors have no potential conflict of interest to disclose.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Vetsika, EK., Konsolakis, G., Aggouraki, D. et al. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. Cancer Immunol Immunother 61, 157–168 (2012). https://doi.org/10.1007/s00262-011-1093-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-011-1093-4